CD-349 | CD349 | CAS#88594-08-5 | calcium channel antagonist

MedKoo Cat#: 526899 | Name: CD-349

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CD-349 is a calcium channel antagonist potentially for the treatment of angina pectoris and hypertension. CD-349 inhibited the noradrenaline (NA)-induced contraction of aortas in Ca2(+)-free medium. The blocking effect of CD349 on neuronal Ca2+ influx, in combination with a cerebral vasodilatory action, may contribute to a favorable effect on ischemic brain damage.

Chemical Structure

CD-349

CAS#88594-08-5

Theoretical Analysis

MedKoo Cat#: 526899

Name: CD-349

CAS#: 88594-08-5

Chemical Formula: C21H24N4O12

Exact Mass: 524.1391

Molecular Weight: 524.44

Elemental Analysis: C, 48.10; H, 4.61; N, 10.68; O, 36.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CD-349; CD 349; CD349.

IUPAC/Chemical Name

3-(2-(nitrooxy)propyl) 5-(3-(nitrooxy)propyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

InChi Key

QSTCLWROWBZZLA-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H24N4O12/c1-12(37-25(32)33)11-35-21(27)18-14(3)22-13(2)17(20(26)34-8-5-9-36-24(30)31)19(18)15-6-4-7-16(10-15)23(28)29/h4,6-7,10,12,19,22H,5,8-9,11H2,1-3H3

SMILES Code

O=C(C1=C(C)NC(C)=C(C(OCCCO[N+]([O-])=O)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCC(O[N+]([O-])=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 524.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Miyata N, Yamaura H, Tsuchida K, Otomo S, Miyajima E. Role of cyclic GMP in inhibitory effects of CD-349 in isolated blood vessels. Gen Pharmacol. 1994 Mar;25(2):267-73. PubMed PMID: 8026725. 2: Ogawa N, Mizuno K, Fukushima K, Suwa T, Satoh T. Metabolic fate of a new dihydropyridine calcium antagonist, CD-349, in rat and dog. Xenobiotica. 1993 Jul;23(7):747-59. PubMed PMID: 8237057. 3: Ogawa T, Nakazato A, Tsuchida K, Hatayama K. Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5-positions. Chem Pharm Bull (Tokyo). 1993 Jun;41(6):1049-54. PubMed PMID: 8370105. 4: Satoh H, Tsuchida K. Comparison of a calcium antagonist, CD-349, with nifedipine, diltiazem, and verapamil in rabbit spontaneously beating sinoatrial node cells. J Cardiovasc Pharmacol. 1993 May;21(5):685-92. PubMed PMID: 7685436. 5: Miyata N, Yamaura H, Tsuchida K, Otomo S. Effects of CD-349 and 8-BrcGMP on isoproterenol-induced relaxation in rabbit aorta precontracted with endothelin-1. Am J Physiol. 1992 Oct;263(4 Pt 2):H1113-8. PubMed PMID: 1329561. 6: Takahashi T, Hisa H, Satoh S. Serotonin-induced vasoconstriction in dog kidney. J Cardiovasc Pharmacol. 1992;20(5):779-84. PubMed PMID: 1280741. 7: Tsuchida K, Kaneko K, Aihara H. Electrophysiological effects of CD-349, a dihydropyridine-type calcium antagonist, on goat cardiac Purkinje fibers. J Cardiovasc Pharmacol. 1991 Nov;18(5):769-76. PubMed PMID: 1723775. 8: Oyama Y, Nakaye T, Akaike N, Tsuchida K. Effect of CD349, a new dihydropyridine derivative Ca2+ antagonist, on the voltage-dependent Ca2+ currents in isolated mammalian brain neurons. Arch Int Pharmacodyn Ther. 1991 Sep-Oct;313:47-62. PubMed PMID: 1816763. 9: Kamata K, Nishiyama H, Miyata N, Kasuya Y. Effects of CD-349, a dihydropyridine derivative, on contraction induced by vasoactive agents in canine basilar artery after subarachnoid hemorrhage. Res Commun Chem Pathol Pharmacol. 1991 May;72(2):143-60. PubMed PMID: 1876747. 10: Miyata N, Tsuchida K, Otomo S. Protein kinase C-mediated contraction in rabbit aorta is inhibited by CD-349, a dihydropyridine derivative. J Cardiovasc Pharmacol. 1991 May;17(5):786-91. PubMed PMID: 1713994. 11: Kamata K, Nishiyama H, Miyata N, Kasuya Y. Changes in responsiveness of the canine basilar artery to endothelin-1 after subarachnoid hemorrhage. Life Sci. 1991;49(3):217-24. PubMed PMID: 2062176. 12: Takahara A, Suzuki-Kusaba M, Hisa H, Satoh S. Effects of a novel Ca2+ entry blocker, CD-349, and TMB-8 on renal vasoconstriction induced by angiotensin II and vasopressin in dogs. J Cardiovasc Pharmacol. 1990 Dec;16(6):966-70. PubMed PMID: 1704991. 13: Tanaka M, Muramatsu M, Aihara H, Otomo S. Interaction of the dihydropyridine calcium antagonist, CD-349, with calmodulin. Biochem Pharmacol. 1990 Sep 1;40(5):991-6. PubMed PMID: 2167684. 14: Miyata N, Tsuchida K, Kaneko K, Tanaka M, Otomo S. Mechanisms of inhibitory effects of CD-349 and K(+)-channel activators on noradrenaline-induced contraction and changes in levels of cyclic GMP in rat aorta. Gen Pharmacol. 1990;21(5):665-9. PubMed PMID: 2177435. 15: Nomura M, Kimura Y, Yoshida M, Satoh S. Antihypertensive effect of a new dihydropyridine calcium entry blocker in conscious hypertensive and normotensive rats. Arzneimittelforschung. 1989 Dec;39(12):1542-5. PubMed PMID: 2624602. 16: Tanaka M, Muramatsu M, Aihara H. Alteration of cyclic GMP metabolism by CD-349, a novel calcium antagonist, and by sodium nitroprusside in bovine intrapulmonary artery and vein. Biochem Pharmacol. 1989 Jun 15;38(12):1985-91. PubMed PMID: 2545208. 17: Tanaka M, Muramatsu M, Aihara H. Uptake of CD-349 and nitrendipine into bovine intrapulmonary artery and vein. J Pharmacobiodyn. 1989 Apr;12(4):228-34. PubMed PMID: 2795432. 18: Izumi Y, Isozumi K, Fukuuchi Y, Gotoh F. Effects of 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation and metabolism in cats. Arzneimittelforschung. 1989 Apr;39(4):438-40. PubMed PMID: 2502125. 19: Muramatsu M, Fujita-Tominaga A, Tanaka M, Ishii Y, Aihara H. A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62. PubMed PMID: 2854176. 20: Kawamura J, Gotoh F, Fukuuchi Y, Amano T, Tanaka K, Uematsu D, Suzuki N, Kobari M, Obara K. Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats. Arzneimittelforschung. 1988 Feb;38(2):221-4. PubMed PMID: 3370067.